BERWYN, PA — Panavance Therapeutics Inc. announced interim results from its Phase 1 clinical trial at the 2024 Visceral Medicine Congress in Leipzig, Germany. The study evaluates the safety and efficacy of misetionamide (GP-2250) combined with gemcitabine for patients with advanced pancreatic ductal adenocarcinoma (PDAC). The trial targets patients who previously received a 5FU regimen like FOLFIRINOX.
This open-label, single-arm trial involves 49 patients across 11 cohorts and aims to establish safety, tolerability, and preliminary efficacy. The interim data showed no severe adverse events during monotherapy. However, during the combination phase, there were five grade 3 and ten grade 4 events, primarily linked to gemcitabine.
Dr. Anup Kasi, from the University of Kansas Cancer Center, highlighted the combination’s potential, stating, “Based on the synergistic effects of misetionamide in combination with gemcitabine, with approximately 40% of patients achieving either a partial response or stable disease.” He emphasized the favorable tumor regression compared to historical results with gemcitabine alone.
Greg Bosch, Chairman and CEO, remarked, “We are pleased to share, for the first time, an interim look at the data from our ongoing Phase 1 dose escalation study.” He expressed optimism for the study’s continuation across four U.S. sites, with further updates anticipated in 2025. This data underscores the potential of the misetionamide-gemcitabine combination as a new treatment option for pancreatic cancer.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.